Edition:
United States

Valneva SE (VLS.PA)

VLS.PA on Paris Stock Exchange

2.92EUR
25 Sep 2017
Change (% chg)

€0.02 (+0.69%)
Prev Close
€2.90
Open
€2.90
Day's High
€2.92
Day's Low
€2.90
Volume
5,950
Avg. Vol
87,336
52-wk High
€3.23
52-wk Low
€2.37

Chart for

About

Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and... (more)

Overall

Beta: 1.91
Market Cap(Mil.): €224.99
Shares Outstanding(Mil.): 77.58
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 81.40 16.08
EPS (TTM): -- -- --
ROI: -- 3.18 14.60
ROE: -- 4.93 14.03

BRIEF-Valneva H1 EBITDA rises to 7.6 million euros

* ‍EBITDA INCREASED STRONGLY IN H1 2017 REACHING EUR 7.6 MILLION (VERSUS. EUR 4.7 MILLION IN H1 2016)​

Aug 31 2017

BRIEF-Valneva appoints David Lawrence as Chief Financial Officer

* LAWRENCE'S AND BENDER'S APPOINTMENTS BY THE COMPANY'S SUPERVISORY BOARD WILL BECOME EFFECTIVE ON AUGUST 7TH AND SEPTEMBER 1ST RESPECTIVELY Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Aug 01 2017

BRIEF-Emergent Biosolutions Inc - ‍announced a licensing agreement with Valneva SE for global exclusive rights to Valneva's zika vaccine technology, ZIKV​

* Emergent Biosolutions Inc - ‍announced a licensing agreement with Valneva SE for global exclusive rights to Valneva's zika vaccine technology, ZIKV​

Jul 26 2017

BRIEF-Valneva receives FDA fast track designation for its lyme disease vaccine candidate VLA15

* REG-VALNEVA RECEIVES FDA FAST TRACK DESIGNATION FOR ITS LYME DISEASE VACCINE CANDIDATE VLA15

Jul 24 2017

BRIEF-Valneva confirms its growth strategy and R&D outlook

* REITERATES THAT IT EXPECTS REVENUES TO REACH EUR 105 TO EUR 115 MILLION IN 2017 AND EBITDA OF EUR 5 TO EUR 10 MILLION

Jun 30 2017

BRIEF-Valneva reduces Q1 net loss to 1.7 million euros

* Q1 NET LOSS REDUCED TO €1.7 MILLION ($1.85 million) IN Q1 2017 COMPARED TO A NET LOSS OF €5.0 MILLION IN Q1 2016

May 11 2017

BRIEF-Valneva signs new EB66 commercial license with Bavarian Nordic

* Announces signing of a new EB66 commercial license with Bavarian Nordic

Apr 18 2017

Earnings vs. Estimates